Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab Vedotin + Rituximab + Chidamide in Untreated Elderly Double Expressor DLBCL
NCT07415980Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of polatuzumab vedotin, tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
polatuzumab vedotintucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07415980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07415980.